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Abstract Bacterial infections in cirrhotic patients with ascites
are associated with a severe prognosis and an increased risk of
death. The microbiological standard tests for the diagnosis of
suspected infection, based on culture test of blood and ascitic
fluid, are, in many cases (30–40 %), negative, even when
patients show symptoms of infection. A multiple culture-
independent protocol was applied and evaluated as a diagnos-
tic and prognostic tool for the detection of bacterial infection
in cirrhotic patients. Sixty-four culture-negative samples ob-
tained from 34 cirrhotic patients, with PMN<250 cells/μl of
ascitic fluid, were screened for the presence of bacterial DNA,
endotoxin, peptidoglycan/β-glucan and microscopically visi-
ble bacterial cells. Correlations between the presence of mul-
tiple markers and various clinical and laboratory parameters
were evaluated. Bacterial DNA was detected in 23 samples
collected from 16 patients; a large part of these samples also
showed the presence of other bacterial markers, which was
associated with a worsening of liver functionality, a higher
incidence of infections during the follow-up and a higher mor-
tality rate in our cohort of cirrhotic patients. We believe that
the detection of additional bacterial markers in bacterial DNA-
positive clinical samples makes the bacterial presence and its
clinical significancemore realistic andmight be useful as early
markers of an ongoing bacterial infection and in establishing a
clinical prognosis.
Introduction
Patients with severe liver diseases are particularly susceptible to
bacterial infections, with an incidence rate reaching 30 % [1]. In
these patients, often presenting cirrhosis and ascites, bacterial
infections are associatedwith a severe prognosis and an increased
risk of death [2–4]. The pathogenic mechanism at the basis of the
development of spontaneous infections is related to a phenome-
non known as bacterial translocation (BT) [5, 6], bywhich viable
enteric bacteria cross the gut wall, reaching themesenteric lymph
nodes, and, from there, the systemic circulation and other loca-
tions. The importance of the sequence of events starting from
bacterial translocation and leading up to bacterial infection in the
cirrhotic patient has been increasingly recognised in recent years
[7, 8]. Numerous factors are probably involved in promoting
pathological BT in cirrhosis, including the overgrowth of intesti-
nal microbiota, the structural and functional alteration of the in-
testinal barrier function and the impaired activity of the gut-
associated lymphoid tissue (GALT) [9, 10]. These pathophysio-
logical alterations are believed to be associated not only with the
translocation of viable bacteria but also with the translocation of
bacterial fragments or components such as DNA [2, 11, 12],
which can induce a marked inflammatory response of the host
immune system, resulting in tissue damage and organ failure
[11–13]. The most frequent infections observed in cirrhotic pa-
tients are spontaneous bacterial peritonitis and urinary tract infec-
tions. Pneumonia, skin and soft tissue infections and sepsis could
also occur. The most frequent causative microorganisms of these
infections are enteric Gram-negative rods, mainly Escherichia
coli and Gram-positive cocci [14]. Early diagnosis and treatment
of these infections are mandatory when managing patients with
cirrhosis and ascites.
Bacterial translocation could be diagnosed by the mesen-
teric lymph node-positive culture, but this diagnostic approach
is quite difficult and rather invasive; therefore, alternative
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approaches to diagnosing BT in humans have been proposed.
Typically, microbiological diagnosis of bacterial infection in
cirrhotic patients is based on culture test of blood (blood cul-
ture) and of ascitic fluid. However, in many cases (30–40 %),
these standard tests are negative, even when patients show
symptoms of infection [6, 15].
The lack of isolation of the involved aetiological agent
might be due to incorrect sampling, inadequate conservation
of the specimen, low microbial concentration in the sample
and the involvement of hardly growing or non-recoverable
bacteria. To overcome this problem, several authors have pro-
posed the detection of bacterial DNA in serum and ascitic
fluid (AF) as an alternative method for the diagnosis of BT.
The clinical significance of the presence of this bacterial mol-
ecule in patient samples has not been completely elucidated,
even though it seems to play a role in inflammatory response
and could be a predictor of poor prognosis in cirrhotic patients
with ascites [2, 12, 16].
In this study, we analysed the possibility of using multiple
microbiological markers to early detect the presence of bacte-
ria in steps preceding a fully developed infection in order to
establish a presumptive diagnosis of infection in patients with
a culture-negative report. Moreover, with the aim of determin-
ing the clinical significance and prognostic value of the pres-
ence of multiple bacterial indicators in culture-negative clini-
cal samples, possible correlations between microbiological
and clinical data were evaluated.
Patients and methods
Patients and clinical samples
A homogeneous group of patients with cirrhosis and ascites
was sequentially enrolled in this study and recruited at the
Gastroenterology Unit of the Polyclinic Hospital Umberto I
in Rome (a tertiary referral centre). The diagnosis of cirrhosis
was made after hepatic biopsy or endoscopy when available,
or on the basis of clinical and biochemical parameters. The
PMN counts in the ascitic fluid were lower than 250 cells/μl in
all the patients.
For each subject, demographic and various clinical and
biochemical parameters were recorded. The severity of chron-
ic liver diseases was evaluated using the following indexes:
the Model for End-Stage Liver Disease (MELD) score and the
Child–Pugh score. Infection events, systemic inflammatory
response syndrome (SIRS) and mortality rate were monitored
for a 12-month period.
Patients with HIV, bacterial infection at hospital admission
(culture-positive blood or AF and PMN>250 cells/AF μl), on
corticosteroid treatment, with immunodepression or any type
of carcinoma or malignancy or ongoing antibiotic therapy
were excluded from the study. The Hospital Ethics
Committee approved the study protocol and informed consent
was obtained from all patients enrolled in the study.
A cohort of 34 patients was included in our study and 64
samples of ascitic fluid and blood were collected. All these
patients underwent one or more therapeutic paracenteses and,
each time, the ascitic fluid was collected. For some patients,
blood samples were collected at the same time. All the sam-
ples were analysed according to the standard microbiological
method. Blood samples were inoculated in aerobic and anaer-
obic blood culture bottles maintained for four days at 37 °C.
Ascitic fluids were inoculated in Columbia blood agar, man-
nitol salt agar, MacConkey agar and Sabouraud agar media.
Moreover, an enrichment step was also performed for each AF
sample by inoculating the fluid in blood culture bottles and
incubating them in aerobiosis and anaerobiosis at 37 °C for
four days. Only those clinical samples with a negative micro-
biological report were subsequently analysed.
Aliquots of ascitic fluid (15 ml) and serum, obtained after
centrifugation of blood samples (5 ml), were centrifuged and
the pellet suspended in 2ml of sterile distilled water and stored
at −80 °C.
About 800 μl of the sample was used to search for bacterial
DNA (bactDNA), 200 μl for endotoxin test, 200 μl for pepti-
doglycan/β-D-glucan and 800 μl of the sample was used for
observing the presence of damaged or intact bacterial cells
under a microscope.
DNA extraction
DNA extraction was performed using a standard method.
Briefly, an aliquot of 800 μl of sample was centrifuged at
10,000 × g for 10 min. The pellet was suspended in lysis
buffer (Tris-EDTA buffer containing 10 % SDS) and the pro-
teins were removed after digestion with proteinase K. Cellular
debris was removed by phenol–chloroform treatment.
Bacterial DNA was recovered by isopropanol precipitation.
The extracted DNA was suspended in 100 μl of sterile
nuclease-free water and quantified using a NanoDrop 1000
Spectrophotometer (Thermo Fisher Scientific, Wilmington,
DE, USA).
PCR protocols
A nested polymerase chain reaction (PCR) protocol with uni-
versal primers BR2 and BR3 [17, 18], targeting a conserved
bacterial chromosomal 16S rRNA gene region, was applied to
the DNA extracted from each of the clinical samples: in the
first step, a region of 1465 bp was amplified, while in the
second step (nested PCR), an amplification region of
1137 bp was selected (Table 1). All the samples containing
bacterial DNA and resulting positive to the nested PCR with
universal primers were then subjected to two PCR protocols
previously developed and targeting Enterobacteriaceae and
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Enterococcus faecalis [9, 18]. The specific target for
Enterobacteriaceae was in a common region of the 16S
rRNA gene (entB), while that of E. faecalis was a 444-bp
fragment located within the penicillin-binding protein 5-
encoding gene (Table 1).
All PCR assays were carried out in a GeneAmp PCR
System 9700 thermal cycler (Perkin Elmer). Each reaction
was performed in a final volume of 50 μl. After an initial
denaturation of 10 min at 95 °C, PCR was conducted with
30–35 cycles consisting of 40 s denaturation at 95 °C, 30–40 s
annealing at adequate annealing temperature and a 40-s exten-
sion period at 72 °C, with a 15-min final extension at 72 °C. In
each run, a negative control, containing sterile and nuclease-
free water instead of DNA, and a positive control, consisting
of purified E. coli or E. faecalis DNA, were included.
The PCR products were analysed in 2 % agarose gel elec-
trophoresis stained by GelRed Nucleic Acid Gel Stain
(Biot ium, CA, USA) and were visual ised by the
ImageMaster Gel Analysis System (Amersham Pharmacia
Biotech, Milan, Italy).
Amplification products were purified with the QIAEX II
Gel Extraction Kit (Qiagen, Crawley, UK) and analysed by
sequencing (BMR Genomics, Padova, Italy). The iden-
tification of DNA sequences was obtained by BLAST at
the National Center for Biotechnology Information
(NCBI) website.
Quantification of bacterial DNA by competitive PCR
A competitive PCR assay was applied to quantify the
bactDNA present in the samples.
With regard to the samples containing E. faecalis DNA,
competitive PCR using the internal standard pbp5 IS
(Table 1), obtained as previously described [19], was applied
for a quantitative evaluation of bacterial DNA. Similarly, for
samples that were positive by EntB-PCR, an internal standard
(IS) derived from the selected fragment of the entB region was
prepared. Briefly, a fragment of 155 bp was eliminated from
the entB sequence by cutting in two TfiI sites. The fragment
obtained was amplifiable by the primers EntB Fwd and EntB
IS (Table 1). Prior to PCR quantitative determination of spe-
cific DNA found in clinical samples, we constructed a stan-
dard curve using 10-fold dilution of E. faecalis and E. coli
DNA suspensions in order to test the concentrations of DNA
ranging from 100 ng to 100 pg.
PCR was conducted as described above, except that PCRs
contained a constant amount of the appropriately diluted IS, as
previously described [19, 20].
Detection of lipopolysaccharide
and peptidoglycan/β-D-glucan in clinical samples
The E-TOXATE test (Sigma-Aldrich, Milan, Italy) and the
Silkworm Larvae Plasma (SLP) Reagent Set (Wako Pure
Chemical Industries, Osaka, Japan) were used, according to
the manufacturers’ instructions, to evaluate the presence of
lipopolysaccharide (LPS) and peptidoglycan/β-D-glucan, re-
spectively, in all samples from the patients included in the
study. All samples were tested in duplicate.
Endotoxin detection procedure: an aliquot of 0.1 ml E-
TOXATE Reagent Working Solution was added to each tube
containing 0.1 ml of the clinical sample, E-TOXATE water
(negative control) and endotoxin standard solution (positive
control), and gently mixed. All samples were incubated for 1 h
at 37 °C. After incubation, tubes were gently removed from
the incubator and slowly inverted to observe the possible for-
mation of compact gelatin. The presence of compact gel for-
mation is considered a positive reaction. All other results (soft
gels, turbidity and increase in viscosity or clear liquid) are
considered a negative test, indicating the absence of LPS.
Peptidoglycan/β-D-glucan detection: for this assay, the
SLP Reagent Set was used. This test is based on the natural
activation of “prophenoloxidase cascade system” in the
haemolymph of the Bombyx mori silkworm by the presence
of peptidoglycan and/or β-D-glucan that causes the formation
of melanin. 200 μl of each sample was added and mixed with
Table 1 Polymerase chain reaction (PCR) primers used in universal nested PCR and in PCR targeting Enterobacteriaceae DNA and Enterococcus
faecalis DNA
Primer Sequence Amplified gene Amplicon size (bp) Primer specificity Reference
BR2 Fwd: AGAGTTTGATCCTGGCTC
Rev: GGTTACCTTGTTACGACTT
16S rRNA 1465 All bacteria Weisburg et al. [17]
BR3 Fwd: CCTACGGGAGGCAGCAG
Rev: GGTTACCTTGTTACGACTT












Enterococcus faecalis del Mar Lleó et al. (1999) [19]
*Amplicon size of fragment used as the internal standard (IS).
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800 μl of sterile distilled water. Samples, sterile distilled water
(negative control) and standard purified peptidoglycan prepa-
ration (positive control) were incubated for 10 min at 80 °C
and, after ice-cooling, used for assay.
100 μl of each sample was mixed with 100 μl of SLP
solution. The development of a black colour after incubation
at 30 °C for 60 min is indicative of melanin formation and the
test is considered positive.
Evaluation of the presence and integrity of bacterial cells
The presence of bacterial cells and their state of integrity was
evaluated by treating the clinical samples with the Live/Dead
kit (Live/Dead BacLight™, Molecular Probes, Eugene, OR,
USA). The test was performed according to the manufac-
turer’s instructions. This method is based on the use of a mix-
ture of two fluorochromes, SYNTO9 and propidium iodide,
with different capabilities of penetrating the bacterial wall and
emitting fluorescence at two different wavelengths (green and
red, respectively). 800 μl of samples were centrifuged at 14,
000 × g for 5 min and suspended in 50 μl of a 1 % NaCl
solution. 5 μl of the dye mixture (3 μl SYNTO9 and 2 μl
propidium iodide) was added to each sample. After 15 min
of incubation in the dark, the sample was filtered (Amicon
0.2 μm) and the filter was directly positioned on a slide and
observed by a fluorescence microscope (Leitz Wetzlar
Orthoplan).
If the cell envelope is intact, the passage of only SYNTO9
that links to the DNA determines a green fluorescence staining
(470–550 nm). If the cell membrane is partially damaged, both
propidium iodide and SYNTO9 can enter the cell, with a
resulting red fluorescence (630–650 nm) [21].
Statistical analysis
With regard to the possible association between microbiolog-
ical data and clinical parameters in patients with liver disease,
all the values are reported as mean ± standard deviation (SD)
and p-values <0.05 were considered significant. Data were
analysed as continuous or categorical by using the Student’s
t-test for parametric data and the Mann–Whitney U-test or the
Wilcoxon test for non-parametric data. The Chi-square test
was used for the comparison of dichotomist data. Logistic
regression analysis was employed to identify possible predic-
tors of infection and in-hospital mortality. Univariate analysis
(log-rank) was used to identify prognostic factors of survival
and the variables selected by this analysis were included in a
multivariate analysis according to a Cox regression model.
The survival curves were created using the Kaplan–Meier
method. The software used for the analysis was Number
Cruncher Statistical System (NCSS) 2007.
Results
Presence and quantification of bacterial DNA
in culture-negative ascitic fluid and serum samples
from cirrhotic patients with ascites
A total of 64 clinical samples, 46 of ascitic fluid and 18 of
blood, were collected from 34 cirrhotic patients with bacterial
culture-negative reports. All the samples were examined for
the presence of bacterial DNA by applying the universal
nested PCR, EntB-PCR and E. faecalis pbp5-PCR protocols.
As shown in Table 2, a total of 19/46 (41 %) AF samples
and 4/18 (22 %) sera resulted positive to PCR targeting bac-
terial DNA. The bactDNA-positive samples were isolated
from 16 different patients. As can be observed in Table 2, nine
patients (AA, AB, AD, AH, AI, AJ, AK, AN and BE) had one
AF sample positive for the presence of bactDNA. Another
three patients (AE, AR and AX) presented two AF-positive
samples. Moreover, four patients, AO, BB, BC and BG,
showed the simultaneous presence of bacterial DNA in ascitic
fluid and blood. All bactDNA-positive samples (23 samples)
were subsequently subjected to EntB-PCR and PCR with
pbp5 primers: 15 samples of AF and three sera were amplified
by entB primers and three AF samples showed the presence of
E. faecalis pbp5 (Table 2).
The amplified bacterial DNA isolated from clinical samples
was associated to specific bacterial genus/species by sequenc-
ing. 74 % of samples (17/23 samples) contained DNA from
Enterobacteriaceae. As indicated in Table 2, identification at
the species level revealed that seven samples contained E. coli
(patients AA, AE, AX and BC), five samples Klebsiella spp.
(patients AH, AR and BG), three samples Enterobacter spp.
(patients AN and BB), one sample Serratia spp. (patient AK)
and one sample Citrobacter freundii (patient AI). The remain-
ing 22 % of samples (5/23) corresponded to Gram-positive
bacteria, namely E. faecalis (three samples, patients AB, AD
and BE) and Staphylococcus aureus (two samples, patient AO,
DNA amplicon identified by sequencing). It was not possible to
identify the species corresponding to the DNA detected in the
sample from patient AJ.
To evaluate the amount of bactDNA present in the culture-
negative clinical samples containing Enterobacteriaceae DNA
or E. faecalis DNA, protocols of competitive PCR using a
specific IS were applied. The results obtained are reported in
Table 3. The quantities of DNA varied largely among the
different samples, with four samples (AH, AI, AR1 and
AR2 ) r e s u l t i n g c e r t a i n l y s i g n i f i c a n t ( DNA
concentrations≥90 ng/ml) and specimens with low levels of
DNA, such as samples AA and BE2 (DNA concentra-
tions <10 ng/ml). Regarding the other positive samples,
DNA concentrations yielded average values. The DNA
extracted from the sample collected from patient AJ
patient resulted not quantifiable.
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Presence of other bacterial markers in AF and blood
samples resulting positive for bacterial DNA
Table 3 shows, in addition to the presence of bactDNA and its
quantification, the presence of lipopolysaccharide (LPS),
peptidoglycan/β-glucan (PG/β-glucan) and bacterial cells (in-
tact and damaged cells viewed under a microscope) in each
one of the AF and blood samples examined. In regard to the
blood samples, the microscopy evaluation with the Live/Dead
kit was not applicable.
Endotoxin was detected in 14 AF and three blood samples
containing bactDNA. As expected, LPS was detected in all
samples containing Enterobacteriaceae DNA, with the
only exception of the sample from patient AJ.
Peptidoglycan/β-glucan was detected in some of the
bactDNA-positive samples: the five samples containing
Gram-positive DNA and another nine samples contain-
ing Enterobacteriaceae (Table 3). In 15 out of 19 sam-
ples of AF that registered positive for bactDNA, the
presence of bacterial cells (intact or damaged) was mi-
croscopically appreciable. In three samples, collected
from patients AA, AK and BE, even if fragments of
bacterial wall were detected, intact and/or damaged cells
were not observed. It should be noted that, in patient
Table 2 Presence of bacterial DNA in ascitic fluid samples and sera (s) determined by universal nested PCR (BR2, BR3), EntB-PCR and pbp5-PCR,
and identification of bacteria (Bact ID) in our cohort of cirrhotic patients (PT)
PT Nested PCR
(BR2, BR3)
EntB-PCR pbp5-PCR Bact ID PT Nested PCR
(BR2, BR3)
EntB- PCR pbp5- PCR Bact ID
AA + + − E. coli AW 1s − − −
AB + − + E. faecalis* AW 2s − − −
AC − − − AX 1 + + − E. coli
AD + − + E .faecalis* AX 2 + + − E. coli
AE 1 + + − E. coli AX 2s − − −
AE 2 + + − E. coli AY − − −
AF − − − AYs − − −
AG − − − AZ − − −
AH + + − Klebsiella spp. AZs − − −
AI + + − C. freundii BA − − −
AJ + + − Undetermined BB 1 − − −
AK + + − Serratia spp. BB 1s − − −
AKs − − − BB 2 + + − Enterobacter spp.
AL − − − BB 2s + + − Enterobacter spp.
AM − − − BC + + − E. coli
AN + + − Enterobacter spp. BCs + + − E. coli
ANs − − − BD − − −
AO + − − S. aureus BDs − − −
AOs + − − S. aureus BE 1 − − −
AP − − − BE 2 + − + E. faecalis*
AQ − − − BE 3 − − −
AR 1 + + − Klebsiella spp. BF 1 − − −
AR 2 + + − Klebsiella spp. BF 2 − − −
AS 1 − − − BF 2s − − −
AS 1s − − − BF 3 − − −
AS 2 − − − BF 4 − − −
AT − − − BF 5 − − −
ATs − − − BG + + − Klebsiella spp.
AU − − − BGs + + − Klebsiella spp.
AUs − − − BH 1 − − −
AV − − − BH 2 − − −
AW 1 − − − BH 2s − − −
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AJ, all the bacterial markers, except bacterial DNA, re-
sulted negative.
Based on the data presented in Table 3, an analysis
of the concordance among the different bacterial
markers was performed for all the clinical samples. All
the samples that resulted negative to the presence of
bactDNA (41 samples collected from 18 patients) also
lacked the other bacterial indicators. Among patients for
which samples contained bactDNA, nine (AB, AD, AH,
AI, AN, AO, AR, AX and BC) showed a concordant
presence of all the expected bacterial markers (endotox-
in, PG/β-glucan and bacterial cells for Gram-negatives
or PG/β-glucan and bacterial cells for Gram-positives).
In five patients (AA, AE, AK, BB and BG), the
bactDNA presence was not associated to detectable
PG/β-glucan. Moreover, in patients AA and AK, the
absence of detectable PG/β-glucan is coexistent with
the lack of fluorescent bacterial cells.
Correlation between microbiological and clinical data
in a series of cirrhotic patients with suspected bacterial
infection
To perform a statistical analysis of the possible correlation
betweenmicrobiological data and clinical parameters, patients
were selected based on the following criteria: having samples
with at least 10 ng of bactDNA and at least two of the expected
bacterial markers. Twelve patients (AB, AD, AE, AH, AI,
AN, AO, AR, AX, BB, BC and BG) complied with established
criteria. These patients, together with another 18 patients whose
samples lacked all the bacterial markers, were subjected to sta-
tistical evaluations. As reported in Table 4, no statistically
Table 3 Quantity of bactDNA
(DNA ng/ml) and presence of
endotoxin (LPS), peptidoglycan/
β-glucan (PG) and bacterial cells
(Bact cells) in samples of AF and
serum (s) collected from patients
(PT). RC: fluorescent red cells,
GC: fluorescent green cells, nd:
not determined, nq: not
quantifiable
Patient DNA (ng/ml) LPS PG Bact cells Patient DNA (ng/ml) LPS PG Bact cells
AA 5 + − − AW 1s − − − nd
AB 20 − + GC AW 2s − − − nd
AC − − − − AX 1 40 + + RC
AD 15 − + RC AX 2 10 + + RC, GC
AE 1 20 + − GC AX 2s − − − nd
AE 2 10 + − RC AY − − − −
AF − − − − AYs − − − nd
AG − − − − AZ − − − −
AH 90 + + RC, GC AZs − − − nd
AI 110 + + RC BA − − − −
AJ nq − − − BB 1 − − − −
AK 10 + − − BB 1s − − − nd
AKs − − − nd BB 2 10 + − GC
AL − − − − BB 2s 10 + − nd
AM − − − − BC 10 + + RC, GC
AN 10 + + GC BCs 15 + + nd
ANs − − − nd BD − − − −
AO nd − + RC BDs − − − nd
AOs nd − + nd BE 1 − − − −
AP − − − − BE 2 5 − + −
AQ − − − − BE 3 − − − −
AR 1 150 + + RC, GC BF 1 − − − −
AR 2 120 + + RC, GC BF 2 − − − −
AS 1 − − − − BF 2s − − − nd
AS 1s − − − nd BF 3 − − − −
AS 2 − − − − BF 4 − − − −
AT − − − − BF 5 − − − −
ATs − − − nd BG 15 + − GC
AU − − − − BGs 10 + − nd
AUs − − − nd BH 1 − − − −
AV − − − − BH 2 − − − −
AW 1 − − − − BH 2s − − − nd
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significant differences were observed in the baseline fre-
quencies of age, sex, mean Child–Pugh score and in the
greater part of basic haemodynamic characteristics be-
tween the two study groups. On the contrary, some
clinical parameters showed a statistically significant cor-
relation with the presence/absence of bacterial markers:
for patients with positive bacterial marker samples, the
C-reactive protein was significantly higher and the mean
arterial pressure significantly lower when compared with
pa t i en t s wi thou t bac te r i a l molecu les (p = 0.02
and <0.001, respectively). A significant relationship ex-
ists also between the presence of bacterial markers and
an MELD score value >15 (p< 0.001). Moreover, a sig-
nificant correlation was also found between the emer-
gence of subsequent infections (75 % of the positive
patients vs. 17 % of patients with samples resulting
negative for bacterial markers, p < 0.05) and SIRS
(58 % of positive patients vs. 6 % of negative patients,
p< 0.05) during a follow-up of one year. In regard to
the survival curve of the different patients (Fig. 1), the
mortality rate, in the 12-month follow-up of the pa-
tients, is significantly higher for the group with positive
bacterial markers. Moreover, these patients have an av-
erage survival rate of 71 days compared with a survival
rate of 220 days calculated for patients with bacterial
markers-negative samples.
Discussion
Although the decision of treating or not a suspected case of
ascites infection relies on PMN count, less than 40 % of these
cases are culturable [22], and this fact, together with a frequent
absence of clinical signs, may delay the diagnosis of bacterial
infection in patients with severe liver diseases and the
Table 4 Clinical parameters of the enrolled patients grouped on the
basis of the presence/absence of bacterial markers in ascitic fluid and
serum samples. Successive infections, systemic inflammatory response
syndrome (SIRS) and death rate reported were registered during the 12-
month follow-up of the patients
Clinical parameters Patients negative for the presence
of all bacterial markers (18/34), mean ± SD
Patients positive for the presence
of at least three bacterial markers (12/34), mean ± SD
Age, years 55 ± 11 56 ± 8
Male sex, n (%) 13 (72.2) 8 (66.6)
MELD score >15, n (%)* 6 (33.3) 10 (83.3)
Mean Child–Pugh score 8.9 ± 0.3 9.35 ± 0.5
C-reactive protein (mg/L)* 11.7 ± 4.5 25.6 ± 7.4
Mean arterial pressure (mmHg)* 80.6 ± 9.5 69.25 ± 2.5
Heart rate (beats/min) 73 ± 18.5 74.5 ± 14.5
Blood WBC/mm3 6485 ± 1064 5812± 3135
Serum creatinine (mg/dL) 1.67 ± 0.7 1.18 ± 0.8
Bilirubin (mg/dL) 4.3 ± 2.2 9.18 ± 5.7
Albumin (g/dL) 3.12 ± 0.25 3.1 ± 0.3
Prothrombin time (INR) 1.48± 0.38 1.98± 0.8
Platelets/mm3 (150,000–400,000) 120,428 ± 30,300 113,214 ± 38,500
Haemoglobin (g/dL) 10.4 ± 2.95 10.36 ± 1.55
Serum sodium (mmol/L) 134.7 ± 8 128.57± 10
Successive infections, n (%)* 3 (16.6) 9 (75)
SIRS, n (%)* 1 (5.5) 7 (58)
Death rate (no. of days)* 220 ± 10 71 ± 8
*p-Value < 0.05
Fig. 1 Survival curves during a 12-month follow-up period in patients
with cirrhosis according to the presence or absence of at least three
considered bacterial markers (p-value = 0.01). BM+, patients registering
positive for the presence of at least three bacterial markers (12/34); BM−,
patients registering negative for bacterial markers (18/34)
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application of a targeted antibiotic treatment. Our study started
from the assumption that in vitro non-recoverable bacterial
forms might be involved in suspected cases of infection in
cirrhotic patients with culture-negative microbiological re-
ports [23–25]. In many cases, culture-negative infections in
cirrhotic patients derived from a bacterial translocation with
the reaching of bacteria or bacterial molecules of ascitic fluid
but not maintaining the recoverability, then resulting not
culturable under standard conditions. Moreover, as a conse-
quence of a former antibiotic treatment, viable but non-
culturable bacteria or fragments of killed bacteria can persist
in body sites, thus justifying the recovery of bacterial compo-
nents. By using DNA amplification protocols, we detected the
presence of bacterial DNA in 36 % of the culture-
negative ascitic fluid and blood samples obtained from
16 of the 34 cirrhotic patients enrolled in the study.
About 70 % of the involved non-recoverable bacteria
were Gram-negative Enterobacteriaceae, a percentage
similar to those reported by other authors [2, 6, 11],
while the DNA detected in the other samples
corresponded to Enterococcus and Staphylococcus
species.
For 17 patients, it was possible to collect matched
AF and peripheral blood samples. In this context, four
patients showed the simultaneous presence of bactDNA
in AF and serum, a fact that might be considered mo-
lecular evidence of bacterial translocation. In three cases
(AK, AN and AX), the presence of bactDNA in AF was
not associated with positivity of serum sample.
Considering that the three AF samples contained a fairly
low quantity of bactDNA, we believe, in agreement
with other researchers [22, 26], that these cases may
represent low bacterial colonisation of AF without sys-
temic infection. Alternatively, it could be considered a
residual permanence of bacterial cells in AF that, in the
presence of stressed conditions, like low bactericidal
capacity and the presence of immune inhibitory factors,
were induced to activate bacterial survival mechanisms
with a block of the division capability but maintenance
of vitality [24].
Bacterial DNA is claimed to be a promising surrogate
marker for BT, a frequent event in patients with cirrhosis
and ascites without overt bacterial infections. Various reports
indicated that it could be indicative of pre-clinical infection or
a persistent source of inflammation in cirrhotic patients with
ascites [2, 11, 22, 25]. However, the clinical significance of the
presence of bacterial DNA inAF is not completely understood
and has been questioned. Moreover, it is important to stress
the need for an accurate interpretation of the results obtained
with molecular methods because of their high sensitivity and
the consequent risk of false-positive results.
To support the clinical significance of the presence of
b a c tDNA in c l i n i c a l s amp l e s w i t h n ega t i v e
microbiological reports in evaluating the possibility of
a bacterial infection, we analysed the concordance of
the presence of DNA with other bacterial markers: the
presence of microscopically visible bacterial cells, in-
cluding damaged bacteria, of endotoxin, an important
virulence factor of Gram-negative bacteria, and of com-
ponents of the bacterial wall also having an immuno-
genic role. All the samples lacking bacterial DNA also
resulted negative for the presence of the other bacterial
markers. On the contrary, the samples that resulted pos-
itive for the presence of at least 10 ng of bactDNA also
contained at least two of the expected bacterial markers,
namely LPS, bacterial cells and, in a number of cases,
components of bacterial cell walls. It has to be stressed
that we encountered some difficulties in some cases in
reading the results from the SLP Reagent Set assay (for
the detection of peptidoglycan/β-glucan), which, in fact,
resulted not sufficiently sensitive in the specific clinical
samples examined. In one case (patient AJ), the only
bacterial marker present was bacterial DNA, indicating
a probable unspecific false-positive result or a high sen-
sitivity of the test.
We believe that the detection of the other bacterial markers
in bactDNA-positive clinical samples makes the bacterial
presence and its clinical significance more realistic in that
those bacterial molecules could be considered, taken as a
whole, as early markers of a possible infection not yet fully
developed. We then propose the detection of these markers as
a complementary approach for diagnosing possible BT and
subsequent infection in cirrhotic patients.
Our proposal of including a battery of bacterial
markers in the monitoring of cirrhotic patients might
also be helpful in establishing a clinical prognosis. A
number of authors [2, 11, 13, 16] have reported that
the bactDNA presence and other bacterial components in AF
of patients with cirrhosis could be considered an indi-
cator of poor diagnosis and worse prognosis. Also from
our data, it is possible to deduce that patients with pos-
itive samples for at least three of the considered bacte-
rial markers showed a worsening of liver functionality
and an alteration of circulatory efficiency. The mortality
rate of these patients was higher and death occurred in
a shorter time. Moreover, only in those patients with
samples containing the three bacterial markers were
these more severe clinical conditions accompanied, dur-
ing the follow-up, with a higher incidence of successive
infections and SIRS.
In conclusion, the individuation in clinical samples of
the various bacterial markers considered here may be an
attractive approach for the early detection of bacteria,
including also those that cannot be divided and recov-
ered by standard microbiological methods based on bac-
teria culture. Early detection of bacteria components in
Eur J Clin Microbiol Infect Dis
clinical samples might be useful for more selective and
appropriate prophylaxis to prevent the development of
serious bacterial infections and to avoid further and se-
rious complications in cirrhotic patients with ascites.
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